oxidopamine has been researched along with candesartan in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, MJ; Labandeira-Garcia, JL; Lanciego, JL; Rodriguez-Perez, AI; Valenzuela, R; Villar-Cheda, B | 1 |
| Guerra, MJ; Labandeira-Garcia, JL; Rodriguez-Perez, AI; Valenzuela, R; Villar-Cheda, B | 2 |
| Mertens, B; Michotte, Y; Sarre, S; Varcin, M | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Guerra, MJ; Labandeira-Garcia, JL; Sierrra-Paredes, G; Villar-Cheda, B | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Labandeira-Garcia, JL; Muñoz, A | 1 |
6 other study(ies) available for oxidopamine and candesartan
| Article | Year |
|---|---|
Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Cell Death; Dopamine; Estradiol; Estrogens; Female; Humans; Neuroglia; Neurons; Ovariectomy; Oxidopamine; Parkinson Disease; Peptidyl-Dipeptidase A; Postmenopause; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Substantia Nigra; Tetrazoles | 2010 |
Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Dopaminergic Neurons; Inflammation Mediators; Interleukin-1beta; Male; Molecular Targeted Therapy; NADPH Oxidases; Nerve Degeneration; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Substantia Nigra; Tetrazoles; Tumor Necrosis Factor-alpha | 2012 |
The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Count; Cell Death; Corpus Striatum; Dopamine; Dopaminergic Neurons; Male; Microdialysis; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra; Tetrazoles | 2011 |
Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Dopaminergic Neurons; Estradiol; Estrogen Replacement Therapy; Female; Nerve Degeneration; Neuroprotective Agents; Ovariectomy; Oxidopamine; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles | 2012 |
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine; Serotonin; Tetrazoles | 2014 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dyskinesia, Drug-Induced; In Vitro Techniques; Interleukin-1beta; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Tetrazoles; Vascular Endothelial Growth Factor A | 2014 |